USFDA issues Form 483 with 10 observations to Lupin, Pithampur

"We are addressing the observations comprehensively and will work with the USFDA to resolve these issues at the earliest," it added.

652
USFDA Form 483
USFDA Form 483

Last Updated on October 9, 2024 by The Health Master

New Delhi: Drug firm Lupin said the US health regulator has issued a Form-483 with ten observations after inspecting its Pithampur Unit-2 manufacturing facility.

The US Food and Drug Administration (USFDA) inspected the plant from March 21 to March 29, 2023.

The inspection closed with issuance of a Form-483 with ten observations, Lupin said in a regulatory filing.

“We are addressing the observations comprehensively and will work with the USFDA to resolve these issues at the earliest,” it added.

As per the USFDA, a Form 483 is issued to a firm’s management at the conclusion of an inspection when the investigator has observed any conditions that in its judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.

In November last year, USFDA had issued Form-483 with eight observations each for product and raw material production centres at Lupin’s Mandideep-based manufacturing facility.

In October 2022, the drugmaker announced that the US health regulator has issued Form-483 with five observations following a pre-approval inspection of its Unit-2 injectable manufacturing facility at Nagpur.

USFDA issues Form 483 with 2 observations to Alembic, Gujarat

USFDA issues Form 483 with 3 observations to Bliss GVS Pharma, Maharashtra

USFDA issues Form 483 with one observation to Torrent, Gujarat

USFDA issues Form 483 with 4 observations to Indoco Remedies, Goa

USFDA issues Form 483 with 8 observations to Cipla for Pithampur facility

USFDA issues Form 483 with 2 observations to Laurus Labs for Visakhapatnam facility

USFDA gives ANDA approval for Gabapentin tablets

NPPA fixed retail price of 25 formulations: March 2023

NPPA announces annual change of 12.12% in Wholesale Price Index

CDSCO gives marketing approval for this Diabetes drug in pre-filled pen

Remdesivir not a wonder drug, affects heart: Study

Drug recall: 55,000 bottles of Colchicine tablets due to this reason

Difference: Disintegration and Dissolution test in pharma industry

How to prepare SOPs in the Pharma Industry

Difference between branded and generic medicines

Understanding DQ, IQ, PQ, and OQ in the Pharma Industry

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon

For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:

YouTube Icon

For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:

YouTube Icon

For informative videos on consumer awareness, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news